The role of CD95 and CD95 ligand in cancer
Abstract CD95 (Fas/APO-1) and its ligand, CD95L, have long been viewed as a death
receptor/death ligand system that mediates apoptosis induction to maintain immune …
receptor/death ligand system that mediates apoptosis induction to maintain immune …
Circulating thyroid cancer biomarkers: Current limitations and future prospects
AM Nixon, X Provatopoulou, E Kalogera… - Clinical …, 2017 - Wiley Online Library
Differentiated thyroid cancer (DTC) is the most common malignancy of the endocrine
system. There has been a significant increase in its incidence over the past two decades …
system. There has been a significant increase in its incidence over the past two decades …
[HTML][HTML] Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
Background Immune checkpoint blockade (ICB) targeting programmed cell death protein 1
and cytotoxic T lymphocyte-associated protein 4 has achieved modest clinical activity as …
and cytotoxic T lymphocyte-associated protein 4 has achieved modest clinical activity as …
Circular RNA CircPRMT5 accelerates proliferation and invasion of papillary thyroid cancer through regulation of miR-30c/E2F3 Axis
C Xue, Y Cheng, J Wu, K Ke, C Miao… - Cancer Management …, 2020 - Taylor & Francis
Background The role of circular RNA (circRNA) in papillary thyroid cancer (PTC) is largely
unknown. This study aims to determine the function and mechanism of circPRMT5 in the …
unknown. This study aims to determine the function and mechanism of circPRMT5 in the …
Fas (CD95)/FasL (CD178) system during ageing
FA Lagunas‐Rangel - Cell Biology International, 2023 - Wiley Online Library
Abstract The Fas/FasL system plays a central role in the physiological regulation of
apoptosis and has been implicated in the pathogenesis of several neoplasms and diseases …
apoptosis and has been implicated in the pathogenesis of several neoplasms and diseases …
Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?
K Kurma, A Boizard-Moracchini, G Galli, M Jean… - … et Biophysica Acta (BBA …, 2021 - Elsevier
Although CD95L (also known as FasL) is still predominantly considered as a death ligand
that induces apoptosis in infected and transformed cells, substantial evidence indicate that it …
that induces apoptosis in infected and transformed cells, substantial evidence indicate that it …
[HTML][HTML] Age-dependent changes in FasL (CD95L) modulate macrophage function in a model of age-related macular degeneration
H Zhao, J Roychoudhury, TA Doggett… - … & visual science, 2013 - jov.arvojournals.org
Purpose.: We examined the effect of aging on Fas ligand (FasL) function in a mouse model
of choroidal neovascularization (CNV). Methods.: Young and aged mice were laser treated …
of choroidal neovascularization (CNV). Methods.: Young and aged mice were laser treated …
[HTML][HTML] Current and emerging biomarkers of cell death in human disease
K Li, D Wu, X Chen, T Zhang, L Zhang, Y Yi… - BioMed research …, 2014 - hindawi.com
Cell death is a critical biological process, serving many important functions within
multicellular organisms. Aberrations in cell death can contribute to the pathology of human …
multicellular organisms. Aberrations in cell death can contribute to the pathology of human …
Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3
AS Ali, A Perren, C Lindskog, S Welin, H Sorbye… - Scientific reports, 2020 - nature.com
Pancreatic neuroendocrine neoplasms (PanNENs) are rare tumours that compose 1–2% of
all pancreatic tumours. Patients with metastatic grade 3 neoplasia are usually treated with …
all pancreatic tumours. Patients with metastatic grade 3 neoplasia are usually treated with …
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid …
RD Harvey, BC Carthon, C Lewis, MS Hossain… - British Journal of …, 2020 - nature.com
Abstract Background Purpose: The combination of a mammalian target of rapamycin
inhibitor and lenalidomide showed enhanced preclinical cytotoxicity. We conducted a phase …
inhibitor and lenalidomide showed enhanced preclinical cytotoxicity. We conducted a phase …